Systemic treatments with tyrosine kinase inhibitor and platinum-based chemotherapy in patients with unresectable or metastatic hepatocholangiocarcinoma
Backgrounds and aims: Even if no systemic treatment is currently validated for unresectable hepato-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKI), and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line sys...
Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
Karger Publishers
2022-06-01
|
Sraith: | Liver Cancer |
Rochtain ar líne: | https://www.karger.com/Article/FullText/525488 |